Table 3.
Characteristic of the subjects stratified by values of the NLR.
| Variable | Low NLR group (<2.31, n=145) | High NLR group (>2.31, n=146) | P |
|---|---|---|---|
| Disease category, n (%) | 0.013 | ||
| CP | 55 (37.9) | 45 (30.8) | |
| PDAC | 29 (20) | 16 (11) | |
| PBLT | 61 (42.1) | 85 (58.2) | |
| Age (year) | 54.70 ± 13.62 | 55.88 ± 12.86 | 0.448 |
| Sex, n (%) | 0.098 | ||
| Male | 75 (51.7) | 90 (61.6) | |
| Female | 70 (48.3) | 56 (38.4) | |
| Body mass index (kg/m2) | 22.18 ± 3.48 | 22.08 ± 3.48 | 0.799 |
| Fasting plasma glucose (mmol/L) | 5.11 (4.65,6.13) | 5.60 (4.87,7.59) | 0.004 |
| Fasting insulin (umol/L)* | 6.13 (3.42,8.83) | 7.30 (3.94,10.95) | 0.046 |
| Fasting c-peptide (nmol/L)# | 0.50 (0.38,0.67) | 0.57 (0.42,0.77) | 0.131 |
| HOMA2 β* | 93.10 (65.95,119.23) | 86.25 (61.08,112.48) | 0.419 |
| HOMA2 IR * | 1.11 (0.89,1.66) | 1.29 (0.94,1.89) | 0.028 |
| HbA1c (%) | 5.9 (5.5,6.3) | 6.0 (5.5,6.5) | 0.424 |
| Total bilirubin (umol/L) | 10.60 (8.20,14.00) | 11.40 (8.10,13.50) | 0,969 |
| Alanine aminotransferase (IU/L) | 17.00 (12.00,28.50) | 18.00 (13.00,28.25) | 0.336 |
| Albumin (g/L) | 41.33 ± 6.77 | 43.17 ± 6.70 | 0.020* |
| Urea (mmol/L) | 289.00 (249.00,338.50) | 297.00 (241.00,359.00) | 0.837 |
| Creatinine (umol/L) | 67.00 (56.00,76.00) | 68.50 (58.00,80.50) | 0.172 |
| Triglycerides (mmol/L) | 1.08 (0.84,1.58) | 1.24 (0.89,1.61) | 0.126 |
| Cholesterol (mmol/L) | 3.95 (3.44,4.54) | 4.07 (3.55,4.72) | 0.251 |
| High density lipoprotein (mmol/L) | 1.21 ± 0.35 | 1.21 ± 0.37 | 0.917 |
| Low density lipoprotein (mmol/L) | 2.28 (1.82,2.80) | 2.45 (1.99,2.91) | 0.126 |
| Total bile acid (umol/L) | 3.70 (1.90,6.45) | 3.90 (2.05,6.20) | 0.678 |
| Hemoglobin (g/L) | 129.18 ± 13.74 | 131.86 ± 17.25 | 0.144 |
| White blood cells (109/L) | 5.12 (4.28,5.97) | 5.98 (5.15,7.24) | <0.0001 |
| Platelets (109/L) | 171.00 (132.00,213.00) | 172.50 (134.75,219.75) | 0.686 |
CP, Chronic pancreatitis; PDAC, pancreatic ductal adenocarcinoma; PBLT, pancreatic benign and low-grade tumors; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; MLR, monocyte-to-lymphocyte ratio; NMR, neutrophil-to-monocyte ratio.
*, 99 patients in the low NLR group and 98 patients in the high NLR group completed insulin- and β cell function-related index testing.
#84 patients in both the low NLR group and the high NLR group completed fasting c-peptide tests.